How many drugs treat Gastric ulcer?

Drug Landscape tracks 10 marketed treatments for Gastric ulcer (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Gastric ulcer?

Most recent: Pepcid — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/gastric-ulcer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gastric ulcer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastric ulcer (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gastric ulcer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Prevacid	lansoprazole	Generic (originally Takeda)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10
Prilosec	omeprazole	AstraZeneca (originally Astra AB)	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19	1989-09-14
Pepcid	famotidine	Generic (originally Yamanouchi/Merck)	Histamine-2 Receptor Antagonist [EPC]	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2	1986-10-01
Zantac	ranitidine	GSK (originally Glaxo)	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Gaviscon	ALGELDRATE	Sanofi	algeldrate		1983-01-01
Valpin	octatropine methylbromide	Endo	octatropine methylbromide	Muscarinic acetylcholine receptor M1	1962-01-01
Valpin	ANISOTROPINE METHYLBROMIDE	Endo	octatropine methylbromide	Muscarinic acetylcholine receptor M1	1962-01-01
Cantil	MEPENZOLATE	Sanofi	Anticholinergic	Muscarinic acetylcholine receptor M2	1956-01-01
Banthine	methanthelinium	Takeda	methantheline	Muscarinic acetylcholine receptor	1951-01-01
Omeprazol	Omeprazol	RenJi Hospital		ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-12 — Pepcid · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 9 drugs in Gastric ulcer
Sanofi · 2 drugs in Gastric ulcer
Endo · 2 drugs in Gastric ulcer
Generic (originally Takeda) · 1 drug in Gastric ulcer
Generic (originally Yamanouchi/Merck) · 1 drug in Gastric ulcer
Genuine Research Center, Egypt · 1 drug in Gastric ulcer
RenJi Hospital · 1 drug in Gastric ulcer
Takeda · 1 drug in Gastric ulcer
Vanderbilt University Medical Center · 1 drug in Gastric ulcer
AstraZeneca (originally Astra AB) · 1 drug in Gastric ulcer
GSK (originally Glaxo) · 1 drug in Gastric ulcer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gastric ulcer:

Cite this brief

Drug Landscape (2026). Gastric ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastric-ulcer. Accessed 2026-06-10.

Gastric ulcer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing